Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 54:1228-1237, doi:10.1016/j.jacc.2009.04.081
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McDermott, M. M.
Right arrow Articles by Lloyd-Jones, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McDermott, M. M.
Right arrow Articles by Lloyd-Jones, D. M.
Related Collections
Right arrowRelated Article

QUARTERLY FOCUS ISSUE: PREVENTION/OUTCOMES: CARDIOVASCULAR GENOMIC MEDICINE

The Role of Biomarkers and Genetics in Peripheral Arterial Disease

Mary M. McDermott, MD* and Donald M. Lloyd-Jones, MD, ScM

Department of Medicine and Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Manuscript received May 16, 2008; revised manuscript received March 16, 2009, accepted April 21, 2009.

* Reprint requests and correspondence: Dr. Mary M. McDermott, Northwestern University Feinberg School of Medicine, 750 North Lake Shore Drive, 10th Floor, Chicago, Illinois 60611 (Email: mdm608{at}northwestern.edu).

Men and women with lower extremity peripheral arterial disease (PAD) have higher levels of inflammatory biomarkers than those without PAD. Observational studies link higher levels of several inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6, tumor necrosis factor-alpha, and soluble adhesion molecules, to 1 or more of the following outcomes in people with PAD: more severe PAD, greater lower extremity functional impairment, more adverse calf skeletal muscle characteristics, greater declines in the ankle brachial index, greater declines in lower extremity performance, and higher rates of cardiovascular morbidity and mortality. Higher levels of inflammatory biomarkers are also associated with poorer outcomes after lower extremity revascularization, including graft restenosis and mortality. Increasing levels of CRP are associated with increased mortality and faster functional decline among people with PAD. Statin therapies reduce cardiovascular event rates and may improve walking performance in men and women with PAD, perhaps in part because statins can reduce inflammation. However, no clinical trials have been performed to establish whether therapies that specifically block or lower inflammatory biomarkers improve outcomes in patients with PAD. Family studies show that heritability of PAD ranges from approximately 20% to 45% after adjusting for atherosclerotic risk factors. A genetic marker for PAD has the potential to identify individuals at increased risk for PAD and may also uncover proteins that can help determine mechanisms of development of lower extremity atherosclerosis. However, a genetic marker for PAD has not been identified.

Key Words: inflammatory biomarkers • ankle brachial index • peripheral arterial disease • genetics • atherosclerosis

Abbreviations and Acronyms
  ABI = ankle brachial index
  B2M = beta-2 microglobulin
  CRP = C-reactive protein
  ICAM = intracellular adhesion molecule
  IL = interleukin
  PAD = peripheral arterial disease
  SAA = serum amyloid A
  sICAM = soluble intercellular adhesion molecule
  sVCAM = soluble vascular cellular adhesion molecule
  VCAM = vascular cellular adhesion molecule


Related Article

Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A26. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
C. L. Wassel, R. Loomba, J. H. Ix, M. A. Allison, J. O. Denenberg, and M. H. Criqui
Family history of peripheral artery disease is associated with prevalence and severity of peripheral artery disease the san diego population study.
J. Am. Coll. Cardiol., September 20, 2011; 58(13): 1386 - 1392.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Amighi, M. Hoke, W. Mlekusch, O. Schlager, M. Exner, M. Haumer, E. Pernicka, R. Koppensteiner, E. Minar, H. Rumpold, et al.
Beta 2 Microglobulin and the Risk for Cardiovascular Events in Patients With Asymptomatic Carotid Atherosclerosis
Stroke, July 1, 2011; 42(7): 1826 - 1833.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. M. Wahlgren and P. K. E. Magnusson
Genetic Influences on Peripheral Arterial Disease in a Twin Population
Arterioscler Thromb Vasc Biol, March 1, 2011; 31(3): 678 - 682.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N. M. Hamburg and G. J. Balady
Exercise Rehabilitation in Peripheral Artery Disease: Functional Impact and Mechanisms of Benefits
Circulation, January 4, 2011; 123(1): 87 - 97.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
F. T. H. Wu, M. O. Stefanini, F. M. Gabhann, C. D. Kontos, B. H. Annex, and A. S. Popel
VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model
Am J Physiol Heart Circ Physiol, June 1, 2010; 298(6): H2174 - H2191.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al.
Highlights of the Year in JACC 2009
J. Am. Coll. Cardiol., January 26, 2010; 55(4): 380 - 407.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement